Adult and Pediatrics

Interventional trials

Gastrointestinal Stromal Tumor (GIST)

All Mutation Types (KIT, PDGFRα D842V, Wild)

1st Line

2nd or 3rd line

1st or 2nd line

3rd or 4th+ Line

SDH-Mutant/deficient GIST

Paraganglioma or Pheochromocytoma

IRB# 24799
Observational study evaluating the long-term safety and efficacy of avapritinib in the first-line treatment of patients with platelet-derived growth factor receptor alpha (PDGFRα) D842Vmutated gastrointestinal stromal tumour (GIST)

IRB# 24058
Phase 3, Randomized, Open-label, Multi-center Study of CGT9486+Sunitinib vs Sunitinib in Patients with Advanced, Unresectable, or Metastatic GIST (PEAK)

IRB# 24390
A First In Human (FIH) Study of IDRX-42 in Participants with Metastatic and/or Unresectable GIST

IRB# 23182
Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced GIST

IRB# 23772
Phase 1, Multi-center, Open-label Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced GIST

IRB# 22463
A Prospective, Multi-Institutional Phase 2 Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

IRB# 24906
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors including Sarcomas

IRB# 21884
An Open-Label, Phase 2 Efficacy Study of Temozolomide in Advanced SDH Mutant/Deficient GIST

http://www.ohsu.edu/research/rda so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold